Copied
 
 
2023, DKK
25.06.2024
Bruttoresultat

-1.854'

Primær drift

-3.250'

Årets resultat

-1.088'

Aktiver

27.079'

Kortfristede aktiver

7.702'

Egenkapital

19.424'

Afkastningsgrad

-12 %

Soliditetsgrad

72 %

Likviditetsgrad

471 %

Resultat
25.06.2024
Årsrapport
2023
25.06.2024
2022
15.06.2023
2021
23.05.2022
2020
02.07.2021
2019
22.05.2020
2018
31.05.2019
2017
19.06.2018
2015
30.06.2017
Nettoomsætning
Bruttoresultat-1.853.676-729.160-4.487.992-3.187.784-3.028.217-7.855.430-5.301.699-2.358.631
Resultat af primær drift-3.250.432-2.005.735-6.952.571-4.420.975-5.098.614-10.803.285-10.790.711-2.738.631
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter31.10831.93231.28218.76869.423000
Finansieringsomkostninger-127.826-310.884-279.878-67.2240000
Andre finansielle omkostninger0000-38.846-12.562-111.159-37
Resultat før skat-3.347.150-2.284.687-7.201.167-4.469.431-5.068.037-10.815.847-10.901.870-2.738.668
Resultat-1.088.011-644.647-5.654.295-3.492.115-3.956.201-7.043.685-10.901.870-2.738.668
Forslag til udbytte00000000
Aktiver
25.06.2024
Årsrapport
2023
25.06.2024
2022
15.06.2023
2021
23.05.2022
2020
02.07.2021
2019
22.05.2020
2018
31.05.2019
2017
19.06.2018
2015
30.06.2017
Kortfristede varebeholdninger00000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 3.997.5032.027.0712.625.8582.528.3084.321.0715.323.8601.052.849115.068
Likvider3.704.2419.048.168228.2336.429.715760.3951.201.43611.958.506129.377
Kortfristede aktiver7.701.74411.075.2392.854.0918.958.0230000
Immaterielle aktiver og goodwill17.723.5447.454.728000004.520.000
Finansielle anlægsaktiver50.54750.54750.54750.54750.54750.54750.5470
Materielle aktiver1.603.2732.073.4547.6157.6157.61522.21315.1360
Langfristede aktiver19.377.3649.578.72958.16258.16258.16272.76065.6834.520.000
Aktiver27.079.10820.653.9682.912.2539.016.1855.139.6286.598.05613.077.0384.764.445
Aktiver
25.06.2024
Passiver
25.06.2024
Årsrapport
2023
25.06.2024
2022
15.06.2023
2021
23.05.2022
2020
02.07.2021
2019
22.05.2020
2018
31.05.2019
2017
19.06.2018
2015
30.06.2017
Forslag til udbytte00000000
Egenkapital19.423.7364.706.358-2.849.0442.805.2514.630.6995.586.90212.630.5874.721.352
Hensatte forpligtelser00000000
Langfristet gæld til banker00000000
Anden langfristet gæld5.546.3915.264.8185.104.90028.815000
Leverandører af varer og tjenesteydelser1.303.551262.686109.999764.174304.000531.19790.38438.093
Kortfristede forpligtelser1.633.80810.401.219496.4791.106.034480.1141.011.154446.4510
Gældsforpligtelser7.655.37215.947.6105.761.2976.210.9340000
Forpligtelser7.655.37215.947.6105.761.2976.210.9340000
Passiver27.079.10820.653.9682.912.2539.016.1855.139.6286.598.05613.077.0384.764.445
Passiver
25.06.2024
Nøgletal
25.06.2024
Årsrapport
2023
25.06.2024
2022
15.06.2023
2021
23.05.2022
2020
02.07.2021
2019
22.05.2020
2018
31.05.2019
2017
19.06.2018
2015
30.06.2017
Afkastningsgrad -12,0 %-9,7 %-238,7 %-49,0 %-99,2 %-163,7 %-82,5 %-57,5 %
Dækningsgrad Na.Na.Na.Na.Na.Na.Na.Na.
Resultatgrad Na.Na.Na.Na.Na.Na.Na.Na.
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning -5,6 %-13,7 %198,5 %-124,5 %-85,4 %-126,1 %-86,3 %-58,0 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal -2.542,9 %-645,2 %-2.484,1 %-6.576,5 %Na.Na.Na.Na.
Soliditestgrad 71,7 %22,8 %-97,8 %31,1 %90,1 %84,7 %96,6 %99,1 %
Likviditetsgrad 471,4 %106,5 %574,9 %809,9 %Na.Na.Na.Na.
Resultat
25.06.2024
Gæld
25.06.2024
Årsrapport
25.06.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 25.06.2024)
Information om virksomhedens regnskabsklasse:The annual report of EYE-GO A/S for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.
Beretning
25.06.2024
Dato for ledelsens godkendelse af årsrapporten:2024-06-25
Oplysning om usædvanlige forhold:Management is responsible for ensuring that the Company’s capital resources are sound at any timeand that sufficient liquidity is available to meet the Company's current and future liabilities as they falldue. The company has raised additional capital in June 2024 to support the company’s growth strategyand expect to continuously raise the necessary capital to support the company's growth strategy. Based on the above, Management is of the opinion that the Company has sufficient capital resourcesfor the coming year, and accordingly, presents the annual report on a going concern basis.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of EYE-GO A/S for the financial year 1 January - 31 December 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:EYE-GO develops disruptive eye care technology that improves the quality of life of people around the world suffering from severe and chronic eye conditions. Revolutionizing the existing eye drop bottle market, the MistGo® product is a novel ocular drug delivery system that is the first viable and truly replacement of the eye drop bottle. MistGo® works by micro-dosing a thin mist into the eye and is part of the next generation delivery systems capable of administering micro-doses for preservative-free liquids. MistGo® is the only system effectively removing all the well-known negative effects and barriers from eye-drop bottles. Patients receive the optimal dose with precise installation every time, minimizing systemic exposure. The product has an eye interface avoiding contamination and ensuring that no parts of the product touch the ocular surface. The technology behind transforms the 6 µL into a precisely targeted mist that is patented in the USA, Europe, and Japan. In 2023 we have finetuned the MistGo® product and made several tests of specific “real-life” customer formulations. These tests have confirmed that MistGo® has a wide performance window regarding viscosity, and the system døs not clog even with sticky formulations. We have delivered MistGo® to clinical studies and we are in the process of developing the first production line. Our business model is to license to pharma companies against milestone payments and generate recurring revenue from long-term supply agreements. EYE-GO targets pharma companies with prescription (Rx) medicine for treatment of chronic eye diseases. The primary segments are glaucoma (a $3. 2B US market) and dry eye disease (“DED”, a $1. 5B US market). Secondary segments are presbyopia (with expected double digit $B revenue within 5-10 years) and myopia. MistGo® is for young companies (new innovative delivery system for new innovative drugs) as well as established companies (life-cycle extension of current drugs).